Similar results were found in a sub-analysis of the FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) trial, which investigated the efficacy of PCSK9 inhibitor evolocumab on acute arterial events across all vascular territories, including coronary, cerebrovascular, and peripheral vascular beds, in patients with stable atherosclerotic cardiovascular disease (ASCVD). The gene discussed is PCSK9; the disease is atherosclerosis.